Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01943851
Additional trial details provided through ANZCTR are available at the end of this record.
Registration number
NCT01943851
Ethics application status
Date submitted
12/09/2013
Date registered
17/09/2013
Date last updated
19/05/2021
Titles & IDs
Public title
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Query!
Scientific title
A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
Query!
Secondary ID [1]
0
0
2013-000445-39
Query!
Secondary ID [2]
0
0
116183
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GSK525762
Experimental: Part 1: GSK525762 QD Cohort - Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
Experimental: Part 1: GSK525762 BID Cohort - Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
Experimental: Part 2: GSK525762 dose expansion cohort - After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.
Treatment: Drugs: GSK525762
GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD)
Query!
Assessment method [1]
0
0
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect. AELD is adverse events leading to permanent discontinuation of study treatment.
Query!
Timepoint [1]
0
0
Up to 86.9 weeks
Query!
Primary outcome [2]
0
0
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Query!
Assessment method [2]
0
0
An event was considered DLT if it occurred within first 3weeks of treatment & met one of following criteria:unless it was clearly established that event is unrelated to treatment:Grade4 neutropenia persisting for >=7 days/febrile neutropenia not responding to treatment within 24hours, Grade4 thrombocytopenia lasting more than 7day & not responding to transfusions/Grade3 thrombocytopenia associated with bleeding (>10milliliter [mL]), Drug-related Grade 3/4 non-hematologic toxicity as described in National Cancer Institute-Common Terminology Criteria for Adverse Events(NCI-CTCAE)version 4.0, Drug-related Grade2 non-hematological toxicity, Grade2 Troponin T elevation(central laboratory>Upper Limit of Normal[ULN]),measured on two separate occasions within 48 hours, Treatment delay of 14 days/greater due to unresolved drug-related toxicity,ALT>=3xULN+bilirubin>=2xULN(>35% direct)/Alanine aminotransferase(ALT) between 3-5xULN with bilirubin<2xULN but with hepatitis symptom/rash/ALT>=5xULN.
Query!
Timepoint [2]
0
0
Up to 3 weeks
Query!
Primary outcome [3]
0
0
Part 1: Number of Participants With Dose Reductions
Query!
Assessment method [3]
0
0
Number of participants with dose reductions due to any reason is presented.
Query!
Timepoint [3]
0
0
Up to 86.9 weeks
Query!
Primary outcome [4]
0
0
Part 1: Number of Participants With Any Dose Interruptions or Delays
Query!
Assessment method [4]
0
0
Number of participants with any dose interruptions/ delays is presented.
Query!
Timepoint [4]
0
0
Up to 86.9 weeks
Query!
Primary outcome [5]
0
0
Part 1: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters
Query!
Assessment method [5]
0
0
Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, prothrombin international normalized ratio (Pro. INR), albumin, amylase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, triglycerides, alkaline phosphatase (ALP). Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.
Query!
Timepoint [5]
0
0
Up to 86.9 weeks
Query!
Primary outcome [6]
0
0
Part 1: Number of Participants With Grade Change From Baseline in Hematology Parameters
Query!
Assessment method [6]
0
0
Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.
Query!
Timepoint [6]
0
0
Up to 86.9 weeks
Query!
Primary outcome [7]
0
0
Part 1: Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method
Query!
Assessment method [7]
0
0
Urine samples were collected to assess glucose, ketones, occult blood, urine protein, and monoclonal protein (monoclonal pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase was defined as any increase in proportional concentrations relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any increase is presented.
Query!
Timepoint [7]
0
0
Up to 86.9 weeks
Query!
Primary outcome [8]
0
0
Part 1: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature
Query!
Assessment method [8]
0
0
Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low <60 beats per minute [bpm] and high >100 bpm); For body temperature (<=35 degrees Celsius or >=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.
Query!
Timepoint [8]
0
0
Up to 86.9 weeks
Query!
Primary outcome [9]
0
0
Part 1: Number of Participants With Increase to Grade 3 From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)
Query!
Assessment method [9]
0
0
DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (<=120 millimeter of mercury [mmHg]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (>=160 mmHg). For DBP: Grade 0 (<=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (>=100 mmHg). Higher grade indicates greater severity. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Number of participants with increase to Grade 3 from Baseline is presented.
Query!
Timepoint [9]
0
0
Up to 86.9 weeks
Query!
Primary outcome [10]
0
0
Part 1: Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings (Investigator Reading)
Query!
Assessment method [10]
0
0
12-lead ECGs were recorded with the participants in a supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Query!
Timepoint [10]
0
0
Up to 86.9 weeks
Query!
Primary outcome [11]
0
0
Part 2: Objective Response Rate (ORR) (MDS Cohort)
Query!
Assessment method [11]
0
0
ORR for MDS cohort is defined as the percentage of participants achieving Complete Response (CR), Marrow CR, CRp (as per CR but platelet count <100 x 10^9 cells/Liter[L]), CRi (as per CR but platelet count <100 x 10^9cells/L or neutrophil count <1 x 10^9 cells/L), or Partial Response (PR) per response criteria. Complete response is defined as bone marrow <=5% myeloblasts with normal maturation of all cell lines, with hemoglobin concentration of >=11 grams per deciliter (g/dL), absolute neutrophil count >=1 x 10^9 cells/L, platelet count >=100x10^9 cells/L and 0% blasts in the peripheral blood. Marrow CR is defined as Bone marrow <=5% myeloblasts and decrease by >=50% over pre-treatment. Objective response rate was determined by the investigator according to international myeloma working group (IMWG) response criteria.
Query!
Timepoint [11]
0
0
Up to 36.4 weeks
Query!
Primary outcome [12]
0
0
Part 2: Objective Response Rate Lasting at Least 4 Months (ORR4) (CTCL Cohorts)
Query!
Assessment method [12]
0
0
ORR4 for CTCL cohorts is defined as the percentage of participants that have achieved a CR or PR lasting at least 4 months per global response criteria and the modified severity weighted assessment tool (mSWAT). ORR4 and 95% exact confidence interval is presented.
Query!
Timepoint [12]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [1]
0
0
Part 1: Overall Response Rate (ORR)- Investigator Assessment
Query!
Assessment method [1]
0
0
ORR is defined as the percentage of participants achieving stringent complete response (sCR), very good partial response (VGPR), partial response (PR) or minimal response (MR) for multiple myeloma (MM); CR or PR for Non-Hodgkin's Lymphoma (NHL); CR, CRp, CRi or PR for Acute Myeloid Leukemia (AML); CR, MR or PR for Myelodysplastic Syndrome (MDS) using the International Working Group (IWG) response criteria and IWG response criteria in myelodysplasia.
Query!
Timepoint [1]
0
0
Up to 86.9 weeks
Query!
Secondary outcome [2]
0
0
Part 1: Area Under the Concentration-time Curve (AUC) From Time Zero to 24 Hours(AUC[0-24]) and AUC Extrapolated to Infinity (AUC[0-inf]) of GSK525762 Following Single Dose Administration
Query!
Assessment method [2]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [2]
0
0
Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [3]
0
0
Part 1: AUC(0-24) and Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK525762 Following Repeat Dose Administration
Query!
Assessment method [3]
0
0
Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. AUC(0-24) represents AUC(0-tau) for repeat dose.
Query!
Timepoint [3]
0
0
Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [4]
0
0
Part 1: Maximum Observed Concentration (Cmax) and Minimum Plasma Concentration (Cmin) of GSK525762 Following Single Dose Administration
Query!
Assessment method [4]
0
0
Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [4]
0
0
Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [5]
0
0
Part 1: Cmax and Cmin of GSK525762 Following Repeat Dose Administration
Query!
Assessment method [5]
0
0
Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [5]
0
0
Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [6]
0
0
Part 1: Trough Concentration (Ctau) of GSK525762 Following Repeat Dose Administration
Query!
Assessment method [6]
0
0
Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [6]
0
0
Week 2 Day 7: Pre-dose on Days 4, 6 and 7
Query!
Secondary outcome [7]
0
0
Part 1: Time of Maximum Concentration (Tmax) of GSK525762 Following Single Dose Administration
Query!
Assessment method [7]
0
0
Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [7]
0
0
Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [8]
0
0
Part 1: Tmax of GSK525762 Following Repeat Dose Administration
Query!
Assessment method [8]
0
0
Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [8]
0
0
Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [9]
0
0
Part 1: Terminal Half Life (T1/2) of GSK525762 Following Single Dose Administration
Query!
Assessment method [9]
0
0
Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [9]
0
0
Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [10]
0
0
Part 1: T1/2 of GSK525762 Following Repeat Dose Administration
Query!
Assessment method [10]
0
0
Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [10]
0
0
Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [11]
0
0
Part 1: Time Invariance (RS) of GSK525762
Query!
Assessment method [11]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. RS was calculated by taking ratio of AUC(0-24) on Week 2 Day 7 to AUC(0-inf) on Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [11]
0
0
Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [12]
0
0
Part 1: Accumulation Ratio (RO) of GSK525762
Query!
Assessment method [12]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis.
Query!
Timepoint [12]
0
0
Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [13]
0
0
Part 2: Apparent Clearance (CL/F) of GSK525762 After Single Dose Administration
Query!
Assessment method [13]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.
Query!
Timepoint [13]
0
0
Week 1 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose
Query!
Secondary outcome [14]
0
0
Part 2: Apparent Clearance (CL/F) of GSK525762 After Repeat Dose Administration
Query!
Assessment method [14]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.
Query!
Timepoint [14]
0
0
Week 3 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose
Query!
Secondary outcome [15]
0
0
Part 2: Apparent Central Volume of Distribution (V1/F) of GSK525762 Following Single Dose Administration
Query!
Assessment method [15]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.
Query!
Timepoint [15]
0
0
Week 1 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose
Query!
Secondary outcome [16]
0
0
Part 2: Apparent Central Volume of Distribution (V1/F) of GSK525762 Following Repeat Dose Administration
Query!
Assessment method [16]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by empirical Bayes estimates. GSK525762 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.
Query!
Timepoint [16]
0
0
Week 3 Day 1: pre-dose and at 0.5 - 2 hour, 4 - 8 hours post-dose
Query!
Secondary outcome [17]
0
0
Part 1: AUC(0-24) and AUC[0-inf] of GSK3529246 (Active Metabolite) Following Single Dose Administration
Query!
Assessment method [17]
0
0
Plasma samples for PK analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [17]
0
0
Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [18]
0
0
Part 1: AUC(0-24) and AUC(0-tau) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration
Query!
Assessment method [18]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762. AUC(0-tau) is AUC(0-24) for repeat dose.
Query!
Timepoint [18]
0
0
Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [19]
0
0
Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Single Dose Administration
Query!
Assessment method [19]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [19]
0
0
Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [20]
0
0
Part 1: Cmax and Cmin of GSK3529246 (Active Metabolite) Following Repeat Dose Administration
Query!
Assessment method [20]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [20]
0
0
Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [21]
0
0
Part 1: Trough Concentration (Ctau) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration
Query!
Assessment method [21]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [21]
0
0
Week 2 Day 7: Pre-dose on Days 4, 6 and 7
Query!
Secondary outcome [22]
0
0
Part 1: Tmax of GSK3529246 (Active Metabolite) Following Single Dose Administration
Query!
Assessment method [22]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [22]
0
0
Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [23]
0
0
Part 1: Tmax of GSK3529246 (Active Metabolite) Following Repeat Dose Administration
Query!
Assessment method [23]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [23]
0
0
Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [24]
0
0
Part 1: T1/2 of GSK3529246 (Active Metabolite) Following Single Dose Administration
Query!
Assessment method [24]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Pharmacokinetic parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [24]
0
0
Week 1 Day 1: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [25]
0
0
Part 1: T1/2 of GSK3529246 (Active Metabolite) Following Repeat Dose Administration
Query!
Assessment method [25]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [25]
0
0
Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [26]
0
0
Part 1: Time Invariance (RS) of GSK3529246 (Active Metabolite)
Query!
Assessment method [26]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. RS was calculated by taking ratio of AUC(0-24) on Week 2 Day 7 to AUC(0-inf) on Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [26]
0
0
Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [27]
0
0
Part 1: Accumulation Ratio (RO) of GSK3529246 (Active Metabolite)
Query!
Assessment method [27]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. Accumulation ratio was calculated by taking ratio of AUC(0-24) in Week 2 Day 7 to AUC (0-24) in Week 1 Day 1. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.
Query!
Timepoint [27]
0
0
Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose; Week 2 Day 7: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose
Query!
Secondary outcome [28]
0
0
Part 2: Apparent Clearance (CL/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration
Query!
Assessment method [28]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. PK parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.
Query!
Timepoint [28]
0
0
Week 1 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose
Query!
Secondary outcome [29]
0
0
Part 2: Apparent Clearance (CL/F) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration
Query!
Assessment method [29]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.
Query!
Timepoint [29]
0
0
Week 3 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose
Query!
Secondary outcome [30]
0
0
Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration
Query!
Assessment method [30]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.
Query!
Timepoint [30]
0
0
Week 1 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose
Query!
Secondary outcome [31]
0
0
Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Repeat Dose Administration
Query!
Assessment method [31]
0
0
Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.
Query!
Timepoint [31]
0
0
Week 3 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose
Query!
Secondary outcome [32]
0
0
Part 2: Change From Baseline in Skindex-29 Domain Scores (Emotional, Functioning and Symptoms Score) for CTCL Cohort
Query!
Assessment method [32]
0
0
The effects of treatment on disease-related symptoms/quality of life was assessed using the Skindex-29 Questionnaire, which inquires about how often (Never, Rarely, Sometimes, Often, All the time) during the previous 4 weeks the participant experienced the effect described in each of 29 items divided into 3 domains: Emotional (10 items), Symptoms (7 items) and Functioning (12 items). Responses to each item are transformed to a linear scale of 100, varying from 0 (no effect) to 100 (effect experienced all the time). Skindex-29 scores were reported as three individual domain scale scores; a scale score is the mean of a participant's responses to items in a given domain. Each domain score ranges from 0 (no effect) to 100 (effect experienced all the time), higher score implies higher impact of skin disease. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is defined is post-dose visit value minus Baseline.
Query!
Timepoint [32]
0
0
Baseline (pre-dose Week1 Day1) and Week 3, Week 7, Week 10, Week 16 and Week 24
Query!
Secondary outcome [33]
0
0
Part 2: Number of Participants With Non-serious AEs and SAEs and AELDs
Query!
Assessment method [33]
0
0
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or, is a congenital anomaly/birth defect. AELD is adverse events leading to permanent discontinuation of study treatment.
Query!
Timepoint [33]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [34]
0
0
Part 2: Number of Participants With Dose Reductions
Query!
Assessment method [34]
0
0
Number of participants with dose reductions due to any reason is presented.
Query!
Timepoint [34]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [35]
0
0
Part 2: Number of Participants With Dose Interruptions/Delays
Query!
Assessment method [35]
0
0
Number of participants with any dose interruptions or delays is presented.
Query!
Timepoint [35]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [36]
0
0
Part 2: Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters
Query!
Assessment method [36]
0
0
Blood samples were collected for the analysis of following clinical chemistry parameters: glucose, Prothrombin international normalized ratio (Pro. INR), albumin, amylase, ALT, AST, bilirubin, calcium, calcium ionized, cholesterol, creatinine, creatine kinase, lipase, potassium, magnesium, sodium, Triglycerides, ALP. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase was defined as an increase relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.
Query!
Timepoint [36]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [37]
0
0
Part 2: Number of Participants With Grade Change From Baseline in Hematology Parameters
Query!
Assessment method [37]
0
0
Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.
Query!
Timepoint [37]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [38]
0
0
Part 2: Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method
Query!
Assessment method [38]
0
0
Urine samples were collected to assess glucose, ketones, occult blood, urine protein. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase was defined as any increase in proportional concentrations relative to Baseline. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any increase is presented.
Query!
Timepoint [38]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [39]
0
0
Part 2: Number of Participants With Worst Case Vital Signs Results Relative to Baseline: Pulse Rate and Body Temperature
Query!
Assessment method [39]
0
0
Vital signs (pulse rate and temperature) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. The clinical concern ranges were: For pulse rate (low <60 beats per minute [bpm] and high >100 bpm); For body temperature (<=35 degrees Celsius or >=38 degrees Celsius). Participants were counted in the worst case category that their value changed to (low, normal or high), unless there was no change in their category. Participants whose value category was unchanged, or whose value became normal, were recorded in the "To Normal or No Change" category. Participants were counted twice if the participant had values that changed "To Low" and "To High", so the percentages may not add to 100%. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date.
Query!
Timepoint [39]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [40]
0
0
Part 2: Number of Participants With Increase to Grade 3 From Baseline in Vital Signs: DBP and SBP
Query!
Assessment method [40]
0
0
DBP and SBP were measured after resting for at least 5 minutes in a supine or semi-recumbent position. They were graded according to NCI-CTCAE version 4.0. For SBP: Grade 0 (<=120 millimeter of mercury [mmHg]), Grade 1 (121-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (>=160 mmHg). For DBP: Grade 0 (<=80 mmHg), Grade 1 (81-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (>=100 mmHg). Higher grade indicates greater severity. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. An increase is defined as an increase in grade relative to Baseline grade. Number of participants with increase to Grade 3 from Baseline is presented.
Query!
Timepoint [40]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [41]
0
0
Part 2: Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings (Investigator Reading)
Query!
Assessment method [41]
0
0
12-lead ECGs were recorded with the participants in a supine position using an ECG machine. Number of participants with worst-case clinically significant and not clinically significant abnormal ECG findings have been presented. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Query!
Timepoint [41]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [42]
0
0
Part 2: Progression Free Survival (PFS)
Query!
Assessment method [42]
0
0
PFS defined as interval of time(in months) between date of first dose & earlier of date of disease progression & date of death due to any cause.Progression is participants(pt's)with MDS & with <5% blasts:>=50% increase in blasts to>5% blasts/pt's with 5-10% blasts:>=50% increase to >10% blasts, for pt's with 10-20% blasts:>=50% increase to >20% blasts,for pt's with 20%-30% blasts:>=50% increase to >30% blasts, for CTCL progression is >=25% increase in skin disease from Baseline/new tumors (T3[1 or more tumors(>=1cm diameter]) in pt's with T1(Limited patches,papules&/or plaques covering <10% of the skin surface;may further stratify into T1a [patch only] versus T1b [plaque+-patch]),T2(Patches,papules/plaques covering >=10% of skin surface;may further stratify into T2a[patch only]versus T2b [plaque+-patch]) orT4(Confluence of erythema covering >=80% body surface area) only skin disease/loss of response in those with CR/PR, increase of skin score of > sum of nadir +50% Baseline score.
Query!
Timepoint [42]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [43]
0
0
Part 2: Duration of Response (DOR)
Query!
Assessment method [43]
0
0
Duration of response is defined as the time from the first documented evidence response (CR or PR lasting 4 months for CTCL; and CR, marrow CR, CRp, Cri or PR for MDS) until the first documented disease progression or death due to any cause. Median and inter-quartile range (first quartile and third quartile) of duration of response are presented.
Query!
Timepoint [43]
0
0
Up to 36.4 weeks
Query!
Secondary outcome [44]
0
0
Part 2: Overall Survival (OS)
Query!
Assessment method [44]
0
0
OS is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. Median and inter-quartile range (first quartile and third quartile) of overall survival are presented.
Query!
Timepoint [44]
0
0
Up to 36.4 weeks
Query!
Eligibility
Key inclusion criteria
Inclusion criteria
- Written informed consent provided.
- Males and females 18 years old or older.
- In Part 1 and, Part 2, subjects must have AML, MM, or NHL. Subjects with AML, are
eligible if they • have relapsed and/or refractory disease, OR are>=65 years of age
and not candidates for or have refused standard chemotherapy. Subjects with multiple
myeloma are eligible if they have progressed despite therapy with an alkylating agent,
proteasome inhibitor, and immunomodulatory agent, either as individual regimens or in
combination. Subjects with NHL are eligible if they have received at least two prior
lines of systemic therapy, including at least one line of immunochemotherapy with an
anti-CD20 antibody (if their tumor expresses CD20).
In Part 2, the NHL cohort will separately enrol subjects with double- and triple hit
lymphoma, so that a minimum of 10 subjects with this subset of disease will be enrolled. To
be eligible for this sub-cohort, tumor sample from the subject must demonstrate
rearrangement and/or overexpression of MYC and either BCL2 and/or BCL6 genes. Evaluation of
double- or triple-hit status may be performed via appropriate local testing, and the
determination of double- or triple-hit diagnosis will be at the discretion of the
investigator and GSK Medical Monitor.
- Subjects with a prior history of stem cell transplant (autologous and/or allogeneic)
are allowed if
- At least 3 months has elapsed from the time of transplant and
- the subject has recovered from transplant-associated toxicities prior to the
first dose of GSK525762, and For subjects with a prior history of allogeneic
transplant,
- the subject has been off systemic immunosuppressive medications (including but
not limited to: cyclosporine, tacrolimus, mycophenolate mofetil, or
corticosteroids) for at least 1 month prior to the first dose of GSK525762.
Topical steroids are permitted
- there are no signs or symptoms of graft versus host disease, other than Grade 1
skin involvement.
- Eastern Cooperative Oncology Group (ECOG) performance status of <=1.
- Subject must be stable enough to be expected to complete dosing through the DLT
observation period as assessed by the investigator.
- Able to swallow and retain orally administered medication and does not have any
clinically significant gastrointestinal abnormalities that may alter absorption such
as malabsorption syndrome or major resection of the stomach or bowels.
- A female subject is eligible to participate if she is of: Non-childbearing potential
defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or
postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases,
a blood sample with simultaneous follicle stimulating hormone (FSH) > 40
milli-International units per milliliter and estradiol < 40 picograms per milliliter
(< 140 picomole per liter) is confirmatory]. Females on hormone replacement therapy
(HRT) and whose menopausal status is in doubt will be required to use one of the
contraception methods defined in protocol if they wish to continue their HRT during
the study. Otherwise, they must discontinue HRT to allow confirmation of
post-menopausal status prior to study enrolment. For most forms of HRT, at least two
to four weeks will elapse between the cessation of therapy and the blood draw; this
interval depends on the type and dosage of HRT. Following confirmation of their
post-menopausal status, they can resume use of HRT during the study without use of a
contraceptive method; Child-bearing potential and agrees to use one of the
contraception methods for an appropriate period of time (as determined by the product
label or investigator) prior to the start of dosing to sufficiently minimize the risk
of pregnancy at that point. Female subjects must agree to use contraception until at
least 7 months after the last dose of study medication; Negative serum pregnancy test
<= 7 days prior to first study drug dose; Female subjects who are lactating must
discontinue nursing prior to the first dose of study treatment and must refrain from
nursing throughout the treatment period and for 5 half-lives of GSK525762 or at least
28 days (whichever is longer) following the last dose of study treatment.
- Male subjects must agree to use one of the methods of contraception specified. This
method must be used from the time of the first dose of study medication until 16 weeks
after the last dose of study medication. In addition, male subjects whose partners are
or become pregnant must continue to use condoms for 7 days after stopping study
medications.
- Adequate organ system function.
- Ability to comply with dietary and tobacco/alcohol abstinence requirements.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
- Haematological malignancy associated with human immunodeficiency virus (HIV) infection
or solid organ transplant or history of known Hepatitis B Antigen or positive
Hepatitis C antibody (confirmed by Recombinant ImmunoBlot Assay [RIBA], if available
or alternately confirmed by Hepatitis C Virus [HCV] Ribonucleic acid [RNA]).
- History or concurrent malignancy of solid tumours, except for below. Exception:
Subjects who have been disease-free for 5 years, or subjects with a history of
completely resected non-melanoma skin cancer or successfully treated in situ carcinoma
are eligible. Subjects with second malignancies that are indolent or definitively
treated may be enrolled even if less than 5 years have elapsed since treatment.
Consult the GSK Medical Monitor if unsure whether second malignancies meet
requirements specified above.
- Currently receiving cancer therapy (chemotherapy, radiation therapy, immuno- therapy,
biologic therapy, hormonal therapy, surgery, and/or tumour embolization).The following
are allowed: Hydroxyurea for proliferative disease, Corticosteroids, Use of
hematopoetic growth factors is permitted at the discretion of the investigator
according to published guidelines (e.g., National Comprehensive Cancer Network (NCCN),
American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH),
etc.). The following are NOT allowed: Investigational anti cancer drug within 2 weeks
prior to the first dose of GSK525762; Major surgery, radiotherapy, or immunotherapy
within 4 weeks of GSK525762 Chemotherapy regimens with delayed toxicity within the
last 4 weeks. Chemotherapy regimens given continuously or on a weekly basis with
limited potential for delayed toxicity within the last 2 weeks.
Nitrosourea or mitomycin C within the last 6 weeks
- Evidence of severe of uncontrolled infection.
- Use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within 7 days
prior to the first dose of GSK525762. Low dose (prophylactic) low molecular weight
heparin (LMWH) is permitted. In addition, INR must be monitored in accordance with
local institutional practices, as appropriate.
- Current use of a prohibited medication or requires any of these medications during
treatment with the investigational drugs. This includes excluding current medications
known or suspected to be associated QT prolongation. In addition, any subject who is
expected to require a QT prolonging medication while on trial should not be enrolled.
- Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated
respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding
episodes). Any serious and/or unstable pre-existing medical (aside from malignancy
exception above), psychiatric disorder, or other conditions that could interfere with
subject's safety, obtaining informed consent or compliance to the study procedures, in
the opinion of the investigator.
- Symptomatic or untreated Central nervous system (CNS) disease, Subjects with a history
of CNS disease (leukemia, lymphoma or myeloma) are permitted to enrol if they have
previously received appropriate therapy and CNS remission has been documented. Subject
with primary CNS lymphoma (defined as isolated CNS lymphoma without systemic
involvement) are excluded from study.
- Cardiac abnormalities as evidenced by any of the following: History or current
clinically significant uncontrolled arrhythmias or hypertension; Clinically
significant conduction abnormalities or arrhythmias, subjects with Bundle Branch
Block; Presence of cardiac pacemaker; History or evidence of current >=Class II
congestive heart failure as defined by New York Heart Association (NYHA); History of
acute coronary syndromes (including unstable angina and myocardial infarction),
coronary angioplasty, or stenting within the past 3 months.
- Any of the following ECG findings or assessments including: Baseline QTcF interval
>=450 milliseconds; Clinically significant ECG assessments should be reviewed by the
site cardiologist prior to study entry.
- GSK525762 is a benzodiazepine class molecule. Any serious known immediate or delayed
hypersensitivity reaction(s) to GSK525762 or idiosyncrasy to drugs chemically related
to the investigational drug.
- Evidence of hemoptysis within the last 7 days.
- History of major gastrointestinal bleeding within the last 3 months or any evidence of
active gastrointestinal bleeding excludes the subject.
- Presence of gastrointestinal disease that would significantly affect compound
absorption.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/05/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/04/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
111
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3002 - East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Pennsylvania
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
Korea, Republic of
Query!
State/province [6]
0
0
Seoul
Query!
Country [7]
0
0
Spain
Query!
State/province [7]
0
0
Barcelona
Query!
Country [8]
0
0
Spain
Query!
State/province [8]
0
0
Madrid
Query!
Country [9]
0
0
Spain
Query!
State/province [9]
0
0
Málaga
Query!
Country [10]
0
0
Spain
Query!
State/province [10]
0
0
Salamanca
Query!
Country [11]
0
0
United Kingdom
Query!
State/province [11]
0
0
Cambridge
Query!
Country [12]
0
0
United Kingdom
Query!
State/province [12]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an open-label repeat dose, multicenter, 2-part study to determine the maximum
tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily
(QD) orally. Part 1 of the study is a dose escalation phase to select the recommended Part 2
dose (RP2D) based on the safety, PK, and PD profiles observed after oral administration of
GSK525762. Eligible subjects with select relapsed refractory hematological malignancies
(acute myeloid leukemia [AML], non-Hodgkin's Lymphoma [NHL]and multiple myeloma [MM]), will
be enrolled in the QD and/or BID dosing cohorts until a MTD is established. Subjects may
continue treatment in the study until disease progression, unacceptable toxicity, or
withdrawal of consent. . Upon determination of the MTD, twice daily (BID) dosing cohorts may
be opened to collect additional safety data and evaluate the preliminary efficacy of
GSK525762 administered BID. Part 2 will explore clinical activity at the MTD or RP2D;
separate expansion cohorts will be planned for acute myeloid leukemia (AML), non-Hodgkin's
Lymphoma (NHL, including an exploratory sub-cohort of subjects with myc and B-Cell Leukemia
(BCL)2 and/or BCL6 rearrangements/overexpression [double- and triple-hit lymphoma]), and
multiple myeloma (MM). This is the first study of this agent to be conducted in subjects with
these relapsed and/or refractory hematological malignancies for which no standard therapies
are anticipated to result in a durable remission.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01943851
Query!
Trial related presentations / publications
Bell C; Fennell K; Chan YC; Rambow F; Yeung M; Vassiliadis D; Lara L; Yeh P; Martelotto L; Rogiers A; Kremer B; Barbash O; Mohammad H; Johanson T; Burr M; Dhar A; Karpinich N; Tian L; Tyler D; MacPherson L; Shi J; Pinnawala N; Fong CY; Papenfuss A; Grimmond S; Dawson SJ; Allan R; Kruger R; Vakoc C; Goode D; Naik S; Gilan O; Lam E; Marine JC; Prinjha R; and Dawson M.Enhancer remodeling overcomes therapeutic resistance driven by epigenetic evolution in cancer.Nature.2019;
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01943851
Additional trial details provided through ANZCTR
Accrual to date
Recruiting in Australia
Recruitment state(s)
VIC
Funding & Sponsors
Primary sponsor
Commercial sector/Industry
Primary sponsor name
GlaxoSmithKline
Primary sponsor address
Primary sponsor country
Ethics approval
Ethics application status
Approved
Public notes
Contacts
Principal investigator
Title
53
0
Prof
Query!
Name
53
0
Mark Dawson
Query!
Address
53
0
Peter MacCallum Cancer Center, Melbourne VIC 3000
Query!
Country
53
0
Australia
Query!
Phone
53
0
Query!
Fax
53
0
Query!
Email
53
0
Query!
Contact person for public queries
Title
54
0
Query!
Name
54
0
Query!
Address
54
0
Query!
Country
54
0
Query!
Phone
54
0
Query!
Fax
54
0
Query!
Email
54
0
[email protected]
Query!
Contact person for scientific queries
Title
55
0
Query!
Name
55
0
Query!
Address
55
0
Query!
Country
55
0
Query!
Phone
55
0
Query!
Fax
55
0
Query!
Email
55
0
[email protected]
Query!
Download to PDF